Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808758 | 0.88 | KMT2A (0.50) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| SCHEMBL3637376 | 0.85 | KMT2A (0.67) | KMT2AMAPTEPHX2NR1H4CA2 | |
| SCHEMBL31510753 | 0.85 | KMT2A (0.50) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| SCHEMBL5936056 | 0.82 | MAPT (0.68) | KMT2AMAPTEPHX2NR1H4CA2 | |
| SCHEMBL27989128 | 0.82 | EPHX2 (0.51) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| SCHEMBL284242 | 0.82 | EPHX2 (0.66) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| SCHEMBL17806562 | 0.81 | EPHX2 (0.60) | KMT2AMAPTEPHX2NR1H4CA2 | |
| SCHEMBL23582988 | 0.80 | PARP10 (0.50) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| SCHEMBL3785596 | 0.80 | EPHX2 (0.47) | KMT2AMAPTEPHX2NR1H4PARP10 | |
| Hydrochloric Acid SCHEMBL5012511 | 0.80 | EPHX2 (0.64) | KMT2AMAPTEPHX2NR1H4PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| CN-107847600-B | Combination therapy of anti-CD 20 antibodies with Bcl-2 inhibitors and MDM2 inhibitors | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3302549-B1 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-9657351-B2 | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist | HOFFMAN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | HOFFMANN-LA ROCHE INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2015-07-30 | — | — | US | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2534132-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | KMT2A 703/4885MAPT 4475/4885EPHX2 2619/4885 |
| US-20150211073-A1 | MRNA-BASED GENE EXPRESSION FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST | MDM2, TP53, TP53BP1 | KMT2A 829/4885MAPT 3662/4885EPHX2 4515/4885 |
| US-20160347852-A1 | Combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor | BCL2L1, MCL1, CD22 | KMT2A 550/4885MAPT 2546/4885EPHX2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.